Results 21 to 30 of about 38,538 (308)

Emerging Antibodies in Cancer Therapy

Advanced NanoBiomed Research, 2023
Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj   +1 more source

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. [PDF]

, 2018
Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of ...
Aliberti S, Bareja R, Bonvini E, Bruna R, Brusa D, Chiaretti S, Chichili GR, Cignetti A, Circosta P, Deaglio S, Elemento O, Elia AR, Foà R, Giacomo FD, Gottardi D, Guarini AR, Inghirami G., Johnson S, Kyriakides PW, Landra I, Machiorlatti R, Massaia M, Monteleone E, Moore PA, Todaro M   +24 more
core   +1 more source

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Cell Discovery, 2022
The highly mutated and transmissible Omicron (BA.1) and its more contagious lineage BA.2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 vaccines and evasion from most anti-SARS-CoV-2 neutralizing antibodies (NAbs).
Yingdan Wang, Xiang Zhang, Yunping Ma, Yanqun Wang, Wuqiang Zhan, Qinwen Zheng, Meng Zhang, Ping Ji, Mei Liu, Qianying Liu, Tingting Sun, Tongyu Zhu, Yumei Wen, Lei Sun, Jincun Zhao, Fan Wu, Zhenguo Chen, Jinghe Huang   +17 more
doaj   +1 more source

Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries

mAbs, 2021
Bispecific antibodies can uniquely influence cellular responses, but selecting target combinations for optimal functional activity remains challenging.
Pallavi Bhatta, Kevin D. Whale, Amy K. Sawtell, Clare L. Thompson, Stephen E. Rapecki, David A. Cook, Breda M. Twomey, Milena Mennecozzi, Laura E. Starkie, Emily M. C. Barry, Shirley J. Peters, Ahmad M. Kamal, Helene M. Finney   +12 more
doaj   +1 more source

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B., Katz, Steven C., Khalili, Marian, Morano, William F., Richard, Scott D., Thadi, Anusha   +5 more
core   +2 more sources

Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. [PDF]

, 2014
Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular calcium signal transducer that is differentially expressed in many cancers. It signals cells for self-renewal, proliferation, invasion, and survival.
Bonavida, Benjamin, Shvartsur, Anna
core   +2 more sources

Single-domain antibodies and their formatting to combat viral infections [PDF]

, 2018
Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies, De Vlieger, Dorien, Rossey, Iebe, Saelens, Xavier, Schepens, Bert   +4 more
core   +2 more sources

Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. [PDF]

, 2013
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Duerr, Harald, Fenn, Sebastian, Gassner, Christian, Griese, Julia J., Hopfner, Karl-Peter, Imhof-Jung, Sabine, Kettenberger, Hubert, Klein, Christian, Moelleken, Joerg, Regula, Joerg Thomas, Schaefer, Wolfgang, Schiller, Christian B., Thomas, Markus   +12 more
core   +3 more sources

Cell-type specific potent Wnt signaling blockade by bispecific antibody. [PDF]

, 2018
Cell signaling pathways are often shared between normal and diseased cells. How to achieve cell type-specific, potent inhibition of signaling pathways is a major challenge with implications for therapeutic development.
Bidlingmaier, Scott, Ha, Kevin D, Lee, Nam-Kyung, Liu, Bin, Sherbenou, Daniel W, Su, Yang, Zhang, Yafeng   +6 more
core   +2 more sources

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies [PDF]

, 2013
Background Since most glioblastomas express both wild-type EGFR and EGFRvIII as well as HER2/neu, they are excellent targets for activated T cells (ATC) armed with bispecific antibodies (BiAbs) that target EGFR and HER2.
A Formentini, A Pfosser, A Thakur, A Thakur, A Thakur, A Yamauchi, AB Heimberger, Archana Thakur, AT Ogden, BF Skinnider, G Jung, GA Niehans, Geoffrey R Barger, HE Lum, Ian M Zitron, J O’Connell, JF Mineo, JK Chan, JM Gall, K Ohshima, K Shiraki, KO Nam, L Davico Bonino, L Ren-Heidenreich, Lawrence G Lum, LG Lum, LM Weiner, M Al-Hajj, M Hahne, M Hishii, M Kawakami, M Sen, M Yankelevich, N Husain, Oxana Norkina, P Saas, PA Davol, RC Grabert, RO Dillman, Sandeep Mittal, SK Jacobs, SK Singh, T Hida, T Nishimura, T Nishimura, T Nitta, TA Dolecek, U Kapp, U Reusch, V Kolenko, X Yuan, Y Oshima   +51 more
core   +4 more sources